Harmony Gold Mining Co. vs Merck & Co., Inc. — how do they compare? Harmony Gold Mining Co. trades at $16.88 (market cap $10.02B), while Merck & Co., Inc. trades at $145.65 (market cap $351.28B). The key difference: Merck & Co., Inc. is far larger — about 35.1× Harmony Gold Mining Co.'s market cap, and Harmony Gold Mining Co. pays the higher dividend (4.63%). Which is the better fit depends on your goals — on Pluang, investors hold Harmony Gold Mining Co. for 45 Days and Merck & Co., Inc. for 98 Days on average.
| HMY | MRK | |
|---|---|---|
Market Cap | $10.02B | $351.28B |
Volume | 3,643,683 | 7,969,665 |
Sector | Basic Materials | Health |
52-Week High | $26.04 | $156.43 |
52-Week Low | $13.32 | $82.49 |
Typical Hold Time | 45 Days | 98 Days |
Enterprise Value | $10.07B | $398.04B |
Dividend Yield | 4.63% | 2.39% |
Signals from Pluang's Aura AI — not financial advice
Harmony Gold Mining (HMY) trades at $16.88, up 2.37% today, but technical indicators signal a bearish trend with moving averages and ADX pointing lower. Fundamentally, the company shows strong profitability with a 29.57% net income margin and robust revenue growth, climbing from $42.6B in 2022 to $73.9B in 2025. Recent earnings have been mixed, with two beats and two misses in the last four quarters. Analyst sentiment is cautious, with a consensus leaning heavily toward Hold.
The outlook for HMY is balanced; its low P/E of 6.02 and expansion into copper production offer value, but bearish technicals and high hold ratings suggest near-term volatility. Key risks include execution of growth projects and commodity price fluctuations, while institutional interest remains a supportive factor.
Merck (MRK) trades at $145.6, up 1.97% today, with a bearish technical signal but strong fundamental performance. Recent earnings have consistently beaten estimates, and the company is expanding its oncology pipeline through the acquisition of Terns Pharmaceuticals. Revenue growth is steady, with 2025 revenue at $65.01B and net income of $18.25B, though 2026 projections show a significant drop in net income to $3.2B. The stock is supported by a high analyst buy consensus of 68.42% and a price target of $158.78.
The outlook for MRK is mixed; strong earnings beats and strategic acquisitions provide upside potential, but high valuation ratios and a projected earnings decline in 2026 pose risks. Investors should weigh the company's robust profitability and analyst support against execution risks and market volatility.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Harmony Gold Mining Co Ltd is a gold mining and exploration company having operations in South Africa and Papua New Guinea (PNG). Its projects include Bambanani, Joel, Masimong, Phakisa, Target 1, Tshepong, Unisel, Doornkop, and Kusasalethu. The group's segments are Tshepong Operations, Bambanani, Joel, Doornkop, Moab Khotsong, Hidden Valley, Target 1, Kusasalethu, Masimong, Unisel, and all other surface operations.
Read more on HMY →Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →